drugset / Trial / NCT00239356
Aripiprazole for Schizophrenia Outpatients Completing BMS Clinical Trials
Phase 3
Completed
119 enrolled
Otsuka Pharmaceutical Development & Commercialization, Inc.
Otsuka America Pharmaceutical · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to provide aripiprazole to schizophrenic outpatients and Community Treated Patients who are currently receiving aripiprazole therapy on another BMS sponsored clinical trial.
Timeline
- Start
- 2003-03
- Primary completion
- 2012-10
- Completion
- 2012-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aripiprazole | Other / unclassified | 10 mg | Oral |
| Subject | Aripiprazole | Other / unclassified | 30 mg | Oral |